1. ALLA AKTIER
  2. NYHETER
  3. IRLAB THERAPEUTICS

IRLAB Therapeutics

Nyheter IRLAB Therapeutics Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

IRLAB to present at Redeye Life Science Day on November 23, 2023

Gothenburg, Sweden, November 20, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the Redeye Life Science Day 2023 on Thursday, November 23, 2023, in Stockholm, Sweden.

Gunnar Olsson, CEO, and Nicholas Waters, EVP and Head of R&D, will participate in the event. The company will give a 2-minute pitch and then participate in a 20-minute Q&A session at 10:00-10:20 CET on November 23, 2023. This event is held at Sergelkonferensen, Mäster Samuelsgatan 42 (ground floor, Redeye building), Stockholm, and is live-streamed.

More information can be found on the event webpage at: https://www.redeye.se/events/915984/redeye-life-science-day-2023

For more information:

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB to present at Redeye Life Science Day on November 23, 2023

Datum 2023-11-20, kl 08:00
Källa MFN
Bifogade filer
IRLAB to present at Redeye Life Science Day on November 23, 2023